CN105641509A - Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application - Google Patents
Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application Download PDFInfo
- Publication number
- CN105641509A CN105641509A CN201610023100.5A CN201610023100A CN105641509A CN 105641509 A CN105641509 A CN 105641509A CN 201610023100 A CN201610023100 A CN 201610023100A CN 105641509 A CN105641509 A CN 105641509A
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- chinese medicine
- monascus
- radix astragali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 20
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 18
- 239000009636 Huang Qi Substances 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 18
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000007902 hard capsule Substances 0.000 claims abstract description 3
- 239000006187 pill Substances 0.000 claims abstract description 3
- 239000007901 soft capsule Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 238000004040 coloring Methods 0.000 claims description 28
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 16
- 241000180649 Panax notoginseng Species 0.000 claims description 16
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 8
- 244000113306 Monascus purpureus Species 0.000 claims description 7
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 7
- 229940057059 monascus purpureus Drugs 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 2
- 241000235395 Mucor Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 229940026314 red yeast rice Drugs 0.000 abstract 4
- 235000013373 food additive Nutrition 0.000 abstract 1
- 239000002778 food additive Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 150000002632 lipids Chemical class 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 9
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 9
- 229960004844 lovastatin Drugs 0.000 description 9
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000008802 xuezhikang Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A traditional Chinese medicine composition for preventing and treating the cardiovascular and cerebrovascular disease can effectively and safely prevent and treat the cardiovascular and cerebrovascular disease. The traditional Chinese medicine composition is prepared from pseudo-ginseng, red yeast rice and radix astragali, wherein pseudo-ginseng, red yeast rice and radix astragali are mixed at the proportion of (10%-90%):(10%-90%):(0%-50%) by dry weight. Effective parts of pseudo-ginseng and extract thereof can serve as the raw materials, effective parts of red yeast rice and extract thereof can serve as the raw materials, and effective parts of radix astragali and extract thereof can serve as the raw materials. The composition prepared from pseudo-ginseng or extract thereof, red yeast rice or extract thereof and radix astragali or extract thereof is prepared through the remarkable synergistic effect of all ingredients in the raw materials instead of simple addition. The composition can be prepared into medically-acceptable preparations such as tablets, capsules (soft capsules or hard capsules), granules, powder, pills, extract and the like, and can be applied to health-care food or food additives.
Description
Technical field:
The invention belongs to the technical field of Chinese medicine composition, it is specifically related to Chinese medicine composition and the application of a kind of prevention and therapy cardiovascular and cerebrovascular diseases.
Background technology:
In recent years, along with growth in the living standard and social population's aging, cardiovascular and cerebrovascular diseases, such as coronary heart disease, acute cerebrovascular disease, peripheral vascular disease etc., sickness rate has the trend that raises year by year, serious harm humans life and health.
Cardiovascular and cerebrovascular diseases is because of caused by the hardening of artery sample to a great extent, and the hardening of artery sample is chronic disease caused by Hazard Factor more than, if Hazard Factor have: hyperlipemia, smoking, hypertension and diabetes etc. Therefore, treatment of starting with from several aspects such as adjusting blood lipid, adjustment blood pressure, adjustment blood sugar, has important clinical meaning to the control of cardiovascular and cerebrovascular diseases.
Existing market is treated hyperlipidemia mainly contain: Statins, the special class of shellfish, bile acid chelating agent and nicotinic acid class. Treat hypertensive medicine the most frequently used: diuretic(s), beta-blockers, calcium antagonist, angiotensin converting enzyme inhibitor and �� receptor-blocking agent. The medicine for the treatment of diabetes has: biguanides, alpha-glucosidase inhibitor and euglycemic agent thiazolidinedione etc. With these medicines, the control of cardiovascular and cerebrovascular diseases is achieved certain effect on clinical, but it is remarkable to take side effect for a long time, and patient's body and mind is caused detrimentally affect.
Therefore, need the feature of Long-term taking medicine according to cardiovascular and cerebrovascular diseases, effective and that toxic side effect is little natural product should be adopted to be advisable.
Summary of the invention:
It is an object of the invention to the deficiency at present control cardiovascular and cerebrovascular diseases medicament, it is provided that the Radix Astragali of a kind of prevention and therapy cardiovascular and cerebrovascular diseases, pseudo-ginseng and fermented red rice composition, the prevention and therapy cardiovascular and cerebrovascular diseases that it can be effective, safe.
The technical scheme of the present invention is as follows:
The Chinese medicine composition of a kind of prevention and therapy cardiovascular and cerebrovascular diseases, it is characterized in that, taking the Radix Astragali, pseudo-ginseng and red colouring agent for food, also used as a Chinese medicine three kinds of components as raw material, in dry matter weight gauge pseudo-ginseng: red colouring agent for food, also used as a Chinese medicine: the Radix Astragali=(10%-90%): (10%-90%): the ratio mixing of (0-50%).
Red colouring agent for food, also used as a Chinese medicine described above can be obtained by following fungi, and described fungi can be monascus (Monacusanka), monascus purpureus (Monacuspurpueus), the monascus that turns white (monacusalbidus), Ba Ke monascus (monacusbarkeri), smoky gray monascus (monacusfulignosus), red monascus (monacusruberrvam), rust monascus (monacusrubiginosus), become red aspergillus (monacusserorubescens) and any one in Mucor shape monascus (monacusmucoroides).
The above-mentioned Radix Astragali and extract, efficient part all can be used as raw material; Pseudo-ginseng (pananxnotoginsng) and extract, efficient part all can be used as raw material; Red colouring agent for food, also used as a Chinese medicine and extract, efficient part all can be used as raw material.
The composition of the present invention can make the various preparation that medically can accept, e.g., and tablet, capsule (soft capsule or hard capsule), granule, powder, pill, extractum etc.
The composition of the present invention can also comprise various medically acceptable carrier and auxiliary material.
Another object of the present invention is also, preparation a series of be convenient to carry and take medicine, protective foods application, or the application as foodstuff additive.
Hereinafter introduce the Radix Astragali in prescription, pseudo-ginseng, red colouring agent for food, also used as a Chinese medicine effect and to the control relevant drug efficacy study of cardiovascular and cerebrovascular diseases.
(1), the Radix Astragali
Radix Astragali slightly warm in nature, taste are sweet, return spleen, lung channel, have tonifying Qi and lifting yang, and benefit defends solid table, promoting pus discharge and tissue regeneration by strengthening QI, effect of profit water detumescence. The chemical composition of the Radix Astragali, pharmacological action and clinical application have been carried out big quantifier elimination by people for many years, and research proves that the treatment of diseases of cardiovascular and cerebrovascular systems and prevention are had significant effect by the Radix Astragali.
1. pair cerebrovascular effect
Experiment shows that the root of large-flowered skullcap can significantly suppress cerebral ischemia, and Radix Astragali Neng Shi rat cerebral tissue MDA content raises, it is to increase SOD is active, scavenging free radicals, is had by membranous structure in addition and necessarily protects left and right. Circulation endothelium cell (CEC) is the significant material reflecting under overall condition that blood vessel endothelium is hindered, and Radix Astragali extract can obviously reduce the quantity of rat CEC, reaches the effect of protection endotheliocyte.
2. the adjustment of pair blood pressure
Blood pressure is had positive and negative dual regulation by the Radix Astragali. Found through experiments the Radix Astragali and there is expansion surrounding blood vessel resistance, reduce artery and right heart preload and improve the effect of heart function. The main component of its step-down is gamma aminobutyric acid (GABA), the signal switching channel mediated by nitrogen protoxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-SGC-CGMC), regulate the function of vascular smooth muscle cell (VSMC), thus adjust blood pressure and coronary artery is had direct dilating effect simultaneously.
3. reducing blood lipid
The Radix Astragali can significantly reduce the serum total cholesterol of hyperlipidemia rat; low density protein cholesterol, MDA level and total cholesterol of liver, MDA content; raise liver SOD, GSH-PX activity; show that the Radix Astragali can reduce rat fat; improve the resistance of oxidation of blood; and the lipidosis of liver can also be reduced, it is to increase the resistance of oxidation of liver, has liver protecting function. The lipid lowerers such as clinical application fenofibrate can cause stem cell diffusivity oedema sex change, though showing that most depressor can reduce blood fat, but because of its liver metabolism promoting liver matter, can increase the weight of hepar damnification, and the Radix Astragali also has the effect protecting liver while reducing blood fat.
(2), pseudo-ginseng
Pseudo-ginseng taste warm in nature hardship sweet, micro-, enters liver, through stomach, has blood stasis removing analgesic, effect of subduing swelling and relieving pain, extensively proving with further investigation its drug effect, and pseudo-ginseng is for cardio-cerebrovascular aspect is effective and toxicity is little.
1. blood pressure falls
Intravenous injection Radix Notoginseng total arasaponins can make the aortic pressure of dog reduce, and diastolic pressure fall is bigger than systolic pressure, and its underpressure and dosage are proportionate. Radix Notoginseng total arasaponins falls blood pressure mainly because of direct vasodilation, it is also possible to relevant with heart contraction.
2. reducing blood-fat
The content of serum lipid is had impact by Radix Notoginseng total arasaponins, and administration group high-density protein (HDL-C), HDL-C/TC value are all obviously greater than control group, but serum triglyceride (TC) and total cholesterol (TG) content and control group comparing difference are not obvious.
3. regulate blood sugar
Blood sugar is had dual regulation by Radix Notoginseng extract, can slightly raise mouse fasting plasma glucose, also tetraoxypyrimidine induced mice hyperglycemia can be had good hypoglycemic activity.
Radix Notoginseng total arasaponins has the raise blood sugar effect of significant collaborative hyperglycemic-glycogenolytic factor. Radix Notoginseng total glycosides RG1There is the blood glucose increasing effect of obvious anti-hyperglycemic-glycogenolytic factor short of money, moreover it is possible to reduce alloxan diabetes mouse blood sugar, and dose-effect relationship is obvious.
4. atherosclerosis
The stiff sample hardening rabbit aorta inner membrance Mottling formation of experimental artery is had obvious restraining effect by Radix Notoginseng total arasaponins, its mechanism of action may with Radix Notoginseng total arasaponins increase arterial wall prostaglandin I2(PGI2), reduce thrombocyte thrombus element A2(TXA2) content, thus correct PGI between modeling rabbit2-TXA2Between unbalance, stablize blood vessel environment relevant.
(3) red colouring agent for food, also used as a Chinese medicine
Red colouring agent for food, also used as a Chinese medicine taste warm in nature is sweet, enters liver, spleen, big large intestine channel, has promoting blood circulation and removing blood stasis, effect of strengthening the spleen to promote digestion, be China's traditional zymotic product, be mainly used in food and medicine aspect. From 1979, from red colouring agent for food, also used as a Chinese medicine, extraction and isolation obtained the cholesterol biosynthesis rate-limiting enzyme 3-hydroxyl-3-glutaryl CoA reductase i.e. lovastatin of inhibitor-MonacolinK() since, both at home and abroad that the research of red colouring agent for food, also used as a Chinese medicine pharmaceutical use is just increasingly extensive and deep.
1. reducing blood-fat
Hyperlipidaemia is had good prevention and therapy effect by Hongqu powder (red colouring agent), and has good anti-atherogenic Mottling formation effect, and dosage becomes positive correlation with drug effect.
The ethanol extraction of red colouring agent for food, also used as a Chinese medicine has the effect reducing hyperlipidaemia quail serum total cholesterol (TC), triglyceride level (TG), low-density lipoprotein (LDL-C), and hypolipidemic activity and lovastatin content are proportionate, research also finds, when as long as the blood concentration of Monacolin constituents reaches 0.001-0.005ug/ml, cholesterol biosynthesis will be suppressed.
In addition, research also finds to there is other Lipid-lowering activities composition in red colouring agent for food, also used as a Chinese medicine, such as Yelkin TTS etc., shows that the reducing blood lipid of red colouring agent for food, also used as a Chinese medicine may be the effect that multicomponent is worked in coordination with.
2. blood pressure falls
Hypertension model rat is shunk and is pressed with impact by red colouring agent for food, also used as a Chinese medicine, the blood pressure of spontaneous hypertension rat (SHR), DOCA-salt form Hypertensive Rats (DHR) can be reduced, but the hypotensive activity of renovascular hypertensive rats rat (RHR) is not obvious, wherein, the hypotensive activity of DHR is better than SHR. DHR is low renin pattern type, and low renin hypertension patient is had good hypotensive activity by prompting red colouring agent for food, also used as a Chinese medicine.
The present invention compared with prior art has the following advantages or positively effect:
1. in red colouring agent for food, also used as a Chinese medicine, reducing blood-fat main component is lovastatin, and life-time service may make cerebral vessels brittle, increases the danger of rupture of blood vessel in brain. The Radix Astragali has the effect of protection cerebrovascular scavenging free radicals, and pseudo-ginseng has effect of vessel softening, and three coordinates the blood fat reducing function that reaches that can be maximum side effect to be reduced to minimum simultaneously.
2. research shows, red colouring agent for food, also used as a Chinese medicine reducing blood lipid and control cardiovascular and cerebrovascular diseases composition and mechanism are complicated, are not only that single component works, but acts on body by many approach; Yelkin TTS in red colouring agent for food, also used as a Chinese medicine and daidzein not only have effect of reducing blood-fat, and have positively effect for improving cardiovascular and cerebrovascular blood supply environment. Red colouring agent for food, also used as a Chinese medicine is used to have more positively effects than chemical drug lovastatin.
3. the medicinal history having had more than 2000 year of the Radix Astragali, the Radix Astragali has enhancing body immunologic function, protects liver, diuresis, anti-ageing, anti-stress, step-down and anti-microbial effect more widely. The Radix Astragali can not only coronary artery dilator, improve blood supply of cardiac muscle, it is to increase immunologic function, and can the process of delaying cell aging, be called as one of Chinese medicine health four treasured. Three high crowds focus mostly in person in middle and old age colony, and the use of the Radix Astragali all the other components can not only be coordinated to reach effect that blood pressure falls in reducing blood-fat, more can improve the deficiency of vital energy, build up health.
4. one of main purpose of patent of the present invention is by the composition of the reducing blood-fat in extensive, the deep research Radix Astragali, pseudo-ginseng and red colouring agent for food, also used as a Chinese medicine and control cardiovascular and cerebrovascular diseases, the composition being intended to find the Radix Astragali or Radix Astragali extract, pseudo-ginseng or Radix Notoginseng extract, red colouring agent for food, also used as a Chinese medicine or Monas cuspurpureus Went extract, wherein each composition has significant synergy.
Embodiment
Below by specific embodiment, the technical scheme of the present invention is described in detail.
Embodiment 1:
Astragalus membranaceus powder (100 order), Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order), in 2:19:19 ratio, mix. Carry out Adjust-blood lipid, adjust blood pressure, adjust blood sugar and atherosclerosis test.
Embodiment 2:
Radix Astragali extract, Radix Notoginseng extract and Monas cuspurpureus Went extract, in 2:19:19 ratio, mix. Carry out Adjust-blood lipid, adjust blood pressure, adjust blood sugar and atherosclerosis test.
Embodiment 3:
Astragalus membranaceus powder (100 order), Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order), in 2:9:9 ratio, mix. Carry out Adjust-blood lipid, adjust blood pressure, adjust blood sugar and atherosclerosis test.
Embodiment 4:
Radix Astragali extract, Radix Notoginseng extract, Monas cuspurpureus Went extract, in 2:9:9 ratio, mix. Carry out Adjust-blood lipid, adjust blood pressure, adjust blood sugar and atherosclerosis test.
Embodiment 5:
Radix Astragali extract, Radix Notoginseng extract, Monas cuspurpureus Went extract, in 1:3:6 ratio, mix. Carry out Adjust-blood lipid, adjust blood pressure, adjust blood sugar and atherosclerosis test.
Embodiment 6:
Radix Notoginseng extract, Monas cuspurpureus Went extract, in 6:4 ratio, mix. Carry out Adjust-blood lipid, adjust blood pressure, adjust blood sugar and atherosclerosis test.
Above example is only in order to the invention will be further described, and the present invention is not by the limitation of embodiment.
Test example: regulating blood lipid action is studied
Test method:
1. rat is fat, the foundation of high blood lipid model: wean male rat, mean body weight 115g, feeds and raises the high fat high cholesterol diet 45d of self-control, body weight increase and TC all obviously higher than negative control group (P < 0.01), model success.
2. lowering blood-fat and reducing weight test: by body weight and TC value high-fat adiposity rat is divided at random 2 groups, namely high-fat adiposity control group (O group), tested material group, often organize rat 20, negative control group (O ' group) continue reservation. Tested material group is fed to raise and is added the high fat high cholesterol diet of tested material (present composition), and O group is fed and raised simple high fat high cholesterol diet, and O ' group is fed and raised normal rats granulated feed, feeds time 30d.
Embodiment 1 Blood Lipid is such as following table 1:(mg/100dl)
: P < 0.01:P < 0.05(and O group compares).
Embodiment 2 Blood Lipid is such as following table 2:(mg/100dl)
: P < 0.01:P < 0.05(and O group compares).
Embodiment 5 Blood Lipid is such as following table 3:(mg/100dl)
: P < 0.01:P < 0.05(and O group compares).
Conclusion
1. test-results shows, tested material (patented composition of the present invention) group compares with high-fat adiposity control group (O group), reduce serum total cholesterol (TC) difference and have pole significance meaning, reduce serum triglyceride (TG) difference and have significance meaning, and high density lipoprotein increasing-cholesterol (HDL-C) difference is without significance meaning, illustrate that said composition has the effect reducing TC and TG preferably.
2. according to test-results convert people daily dosage be 0.6g, further conversion people daily lovastatin dosage is 4.5mg(is 1.5% calculating by lovastatin content in red colouring agent for food, also used as a Chinese medicine).
3. according to Beijing University dimension letter XUEZHIKANG JIAONANG (product batch number: 20150513) defined every containing lovastatin must not less than 2.5mg, one time 2,2 times on the one calculate, people daily lovastatin dosage be at least 10.0mg.
4. people's daily lovastatin dosage, XUEZHIKANG JIAONANG is approximately 2 times of patented composition of the present invention, it thus is seen that each composition has synergy really in said composition.
Claims (9)
1. a composition for prevention and therapy cardiovascular and cerebrovascular diseases, taking the Radix Astragali, pseudo-ginseng and red colouring agent for food, also used as a Chinese medicine as raw material, it is characterised in that: by dry matter weight gauge, in pseudo-ginseng: red colouring agent for food, also used as a Chinese medicine: the Radix Astragali=(10%-90%): (10%-90%): (0%-50%) ratio mixes.
2. composition as claimed in claim 1, its feature in: red colouring agent for food, also used as a Chinese medicine described above can be obtained by following fungi, described fungi can be monascus (Monacusanka), monascus purpureus (Monacuspurpueus), turn white monascus (monacusalbidus), Ba Ke monascus (monacusbarkeri), smoky gray monascus (monacusfulignosus), red monascus (monacusruberrvam), rust monascus (monacusrubiginosus), become any one in red aspergillus (monacusserorubescens) and Mucor shape monascus (monacusmucoroides).
3. composition as claimed in claim 1, it is characterised in that: the Radix Astragali and extract, efficient part all can be used as raw material.
4. composition as claimed in claim 1, it is characterised in that: pseudo-ginseng (Panaxnotoginseng) and extract, efficient part all can be used as raw material.
5. composition as claimed in claim 1, it is characterised in that: red colouring agent for food, also used as a Chinese medicine and extract, efficient part all can be used as raw material.
6. composition as claimed in claim 1, it is characterised in that: said composition can make the various preparation that medically can accept, and is specially: tablet, capsule, granule, powder, pill, extractum.
7. composition according to claim 6, it is characterised in that: described capsule is soft capsule or hard capsule.
8. composition as described in claim 1-7 any claim preparation a series of be convenient to carry and take medicine, protective foods application.
9. composition as described in claim 1-7 any claim is as the application of foodstuff additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610023100.5A CN105641509A (en) | 2016-01-14 | 2016-01-14 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610023100.5A CN105641509A (en) | 2016-01-14 | 2016-01-14 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105641509A true CN105641509A (en) | 2016-06-08 |
Family
ID=56487423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610023100.5A Pending CN105641509A (en) | 2016-01-14 | 2016-01-14 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105641509A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106890307A (en) * | 2017-03-21 | 2017-06-27 | 中国中医科学院中医基础理论研究所 | A kind of Chinese medicine composition with effect for reducing blood fat |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383871A (en) * | 2002-05-27 | 2002-12-11 | 云大科技股份有限公司 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
| CN1557403A (en) * | 2004-01-14 | 2004-12-29 | 陈玲玲 | Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method |
| CN101721456A (en) * | 2010-01-30 | 2010-06-09 | 刘秀芬 | Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
-
2016
- 2016-01-14 CN CN201610023100.5A patent/CN105641509A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1383871A (en) * | 2002-05-27 | 2002-12-11 | 云大科技股份有限公司 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
| CN1557403A (en) * | 2004-01-14 | 2004-12-29 | 陈玲玲 | Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method |
| CN101721456A (en) * | 2010-01-30 | 2010-06-09 | 刘秀芬 | Antiatherosclerotic Chinese traditional medicine for treating cardiovascular and cerebrovascular diseases and method for preparing phospholipid complex formulation thereof |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106890307A (en) * | 2017-03-21 | 2017-06-27 | 中国中医科学院中医基础理论研究所 | A kind of Chinese medicine composition with effect for reducing blood fat |
| CN106890307B (en) * | 2017-03-21 | 2018-07-10 | 中国中医科学院中医基础理论研究所 | A kind of Chinese medicine composition with effect for reducing blood fat |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091315B (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| AU2017101878A4 (en) | Gynostemma pentaphyllum containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia, and gout | |
| CN102716471A (en) | Anti-hyperlipidemia health-care product | |
| CN101450095A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| EP2340839A1 (en) | A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid | |
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN109045224A (en) | A kind of sunflower disk semen coicis compound and the purposes in treatment hepatic injury | |
| CN106376927A (en) | Health care product with auxiliary protective effect on chemical liver injury | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN105232976B (en) | Composition for preventing or/and treating sub-health | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN104740425A (en) | Pharmaceutical composition for treating rheumatic arthralgia, preparation method and application of pharmaceutical composition | |
| CN105641509A (en) | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application | |
| CN106668451B (en) | A kind of Chinese medicine composition and its application | |
| CN1183935C (en) | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases | |
| CN101433667A (en) | Pharmaceutical composition with function for reducing blood sugar and preparation method thereof | |
| CN106962910B (en) | Health-care composition for reducing blood pressure | |
| CN111658746B (en) | Traditional Chinese medicine composition for treating alcoholic fatty liver and preparation method thereof | |
| CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN101450174A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN1736261A (en) | Alcohol-dissolving liver-protecting healthy food | |
| CN101167763B (en) | Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN112439030A (en) | Medicine for quickly reducing uric acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160608 |